Abstract
The ubiquitin-proteasome pathway is involved in intracellular protein turnover and plays an essential function in many cellular processes, thus contributing to cellular homeostasis. The observation that proteasome inhibitors are able to induce apoptosis preferentially in tumor cells opened the way to their use as potential drugs. One of these drugs, bortezomib, was introduced in cancer therapy and its use was approved for the treatment of multiple myeloma and mantle cell lymphoma. The investigation of the mechanisms through which bortezomib causes cell death of cancer cells showed that this drug affects many cellular pathways and many of its effects cannot be related to proteasome inhibition. These observations, as well as the occurrence of bortezomib resistance observed in some myeloma patients treated with this drug, prompted the study of new proteasome inhibitors. These studies have lead to a new generation of proteasome inhibitors, some of them exhibiting the property of selective proteasome inhibition and efficacy in cancer therapy without inducing the side effects elicited by bortezomib. The ensemble of these drugs offers the scenario of the possible development of a family of proteasome inhibitors, contributing a drug arsenal for the therapy of cancer and other diseases.
Current Drug Targets
Title: Proteasome Inhibitors in Cancer Therapy
Volume: 10 Issue: 10
Author(s): Ugo Testa
Affiliation:
Abstract: The ubiquitin-proteasome pathway is involved in intracellular protein turnover and plays an essential function in many cellular processes, thus contributing to cellular homeostasis. The observation that proteasome inhibitors are able to induce apoptosis preferentially in tumor cells opened the way to their use as potential drugs. One of these drugs, bortezomib, was introduced in cancer therapy and its use was approved for the treatment of multiple myeloma and mantle cell lymphoma. The investigation of the mechanisms through which bortezomib causes cell death of cancer cells showed that this drug affects many cellular pathways and many of its effects cannot be related to proteasome inhibition. These observations, as well as the occurrence of bortezomib resistance observed in some myeloma patients treated with this drug, prompted the study of new proteasome inhibitors. These studies have lead to a new generation of proteasome inhibitors, some of them exhibiting the property of selective proteasome inhibition and efficacy in cancer therapy without inducing the side effects elicited by bortezomib. The ensemble of these drugs offers the scenario of the possible development of a family of proteasome inhibitors, contributing a drug arsenal for the therapy of cancer and other diseases.
Export Options
About this article
Cite this article as:
Testa Ugo, Proteasome Inhibitors in Cancer Therapy, Current Drug Targets 2009; 10 (10) . https://dx.doi.org/10.2174/138945009789577909
DOI https://dx.doi.org/10.2174/138945009789577909 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Antitumoral Alkylphospholipids Alter Cell Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Applications of Michael Addition Reaction in Organic Synthesis
Current Organic Synthesis Clinical Immunotherapy of B-Cell Malignancy Using CD19-Targeted CAR T-Cells
Current Gene Therapy Paris Saponin VII Induces Apoptosis and Cell Cycle Arrest in Erythroleukemia Cells by a Mitochondrial Membrane Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews Viral Origins of Human Cancer
Current Medicinal Chemistry EZN-2208 (PEG-SN38), A 40 kDa Polyethylene Glycol (PEG) Conjugate, As an Anticancer Agent: Review of Preclinical and Clinical Data
Current Bioactive Compounds Diketo Acids Derivatives as Integrase Inhibitors: The War Against the Acquired Immunodeficiency Syndrome
Recent Patents on Anti-Infective Drug Discovery Understanding XPO1 Target Networks Using Systems Biology and Mathematical Modeling
Current Pharmaceutical Design Mitochondrial VDAC1: Function in Cell Life and Death and a Target for Cancer Therapy
Current Medicinal Chemistry Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Natural Product Inhibitors of the Ubiquitin-Proteasome Pathway
Current Drug Targets Potential Therapeutic Benefits of Maintaining Mitochondrial Health in Peripheral Neuropathies
Current Neuropharmacology Testicular Germ Cell Tumors: A Paradigm for the Successful Treatment of Solid Tumor Stem Cells
Current Cancer Therapy Reviews Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology Cyclooxygenase-2 Inhibition and Gastric Cancer
Current Pharmaceutical Design Molecular Targets for the Treatment of Testicular Germ Cell Tumors
Mini-Reviews in Medicinal Chemistry The Putative Use of Lithium in Alzheimer’s Disease
Current Alzheimer Research